Cargando…
Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer
OBJECTIVE: To investigate whether a radiomics model can help to improve the performance of PI-RADS v2.1 in prostate cancer (PCa). METHODS: This was a retrospective analysis of 203 patients with pathologically confirmed PCa or non-PCa between March 2015 and December 2016. Patients were divided into a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925826/ https://www.ncbi.nlm.nih.gov/pubmed/33680954 http://dx.doi.org/10.3389/fonc.2020.631831 |
_version_ | 1783659335052689408 |
---|---|
author | Li, Mou Yang, Ling Yue, Yufeng Xu, Jingxu Huang, Chencui Song, Bin |
author_facet | Li, Mou Yang, Ling Yue, Yufeng Xu, Jingxu Huang, Chencui Song, Bin |
author_sort | Li, Mou |
collection | PubMed |
description | OBJECTIVE: To investigate whether a radiomics model can help to improve the performance of PI-RADS v2.1 in prostate cancer (PCa). METHODS: This was a retrospective analysis of 203 patients with pathologically confirmed PCa or non-PCa between March 2015 and December 2016. Patients were divided into a training set (n = 141) and a validation set (n = 62). The radiomics model (Rad-score) was developed based on multi-parametric MRI including T2 weighted imaging (T2WI), diffusion weighted imaging (DWI), apparent diffusion coefficient (ADC) imaging, and dynamic contrast enhanced (DCE) imaging. The combined model involving Rad-score and PI-RADS was compared with PI-RADS for the diagnosis of PCa by using the receiver operating characteristic curve (ROC) analysis. RESULTS: A total of 112 (55.2%) patients had PCa, and 91 (44.8%) patients had benign lesions. For PCa versus non-PCa, the Rad-score had a significantly higher area under the ROC curve (AUC) [0.979 (95% CI, 0.940–0.996)] than PI-RADS [0.905 (0.844–0.948), P = 0.002] in the training set. However, the AUC between them was insignificant in the validation set [0.861 (0.749–0.936) vs. 0.845 (0.731–0.924), P = 0.825]. When Rad-score was added to PI-RADS, the performance of the PI-RADS was significantly improved for the PCa diagnosis (AUC = 0.989, P < 0.001 for the training set and AUC = 0.931, P = 0.038 for the validation set). CONCLUSIONS: The radiomics based on multi-parametric MRI can help to improve the diagnostic performance of PI-RADS v2.1 in PCa. |
format | Online Article Text |
id | pubmed-7925826 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79258262021-03-04 Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer Li, Mou Yang, Ling Yue, Yufeng Xu, Jingxu Huang, Chencui Song, Bin Front Oncol Oncology OBJECTIVE: To investigate whether a radiomics model can help to improve the performance of PI-RADS v2.1 in prostate cancer (PCa). METHODS: This was a retrospective analysis of 203 patients with pathologically confirmed PCa or non-PCa between March 2015 and December 2016. Patients were divided into a training set (n = 141) and a validation set (n = 62). The radiomics model (Rad-score) was developed based on multi-parametric MRI including T2 weighted imaging (T2WI), diffusion weighted imaging (DWI), apparent diffusion coefficient (ADC) imaging, and dynamic contrast enhanced (DCE) imaging. The combined model involving Rad-score and PI-RADS was compared with PI-RADS for the diagnosis of PCa by using the receiver operating characteristic curve (ROC) analysis. RESULTS: A total of 112 (55.2%) patients had PCa, and 91 (44.8%) patients had benign lesions. For PCa versus non-PCa, the Rad-score had a significantly higher area under the ROC curve (AUC) [0.979 (95% CI, 0.940–0.996)] than PI-RADS [0.905 (0.844–0.948), P = 0.002] in the training set. However, the AUC between them was insignificant in the validation set [0.861 (0.749–0.936) vs. 0.845 (0.731–0.924), P = 0.825]. When Rad-score was added to PI-RADS, the performance of the PI-RADS was significantly improved for the PCa diagnosis (AUC = 0.989, P < 0.001 for the training set and AUC = 0.931, P = 0.038 for the validation set). CONCLUSIONS: The radiomics based on multi-parametric MRI can help to improve the diagnostic performance of PI-RADS v2.1 in PCa. Frontiers Media S.A. 2021-02-17 /pmc/articles/PMC7925826/ /pubmed/33680954 http://dx.doi.org/10.3389/fonc.2020.631831 Text en Copyright © 2021 Li, Yang, Yue, Xu, Huang and Song http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Li, Mou Yang, Ling Yue, Yufeng Xu, Jingxu Huang, Chencui Song, Bin Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer |
title | Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer |
title_full | Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer |
title_fullStr | Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer |
title_full_unstemmed | Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer |
title_short | Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer |
title_sort | use of radiomics to improve diagnostic performance of pi-rads v2.1 in prostate cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925826/ https://www.ncbi.nlm.nih.gov/pubmed/33680954 http://dx.doi.org/10.3389/fonc.2020.631831 |
work_keys_str_mv | AT limou useofradiomicstoimprovediagnosticperformanceofpiradsv21inprostatecancer AT yangling useofradiomicstoimprovediagnosticperformanceofpiradsv21inprostatecancer AT yueyufeng useofradiomicstoimprovediagnosticperformanceofpiradsv21inprostatecancer AT xujingxu useofradiomicstoimprovediagnosticperformanceofpiradsv21inprostatecancer AT huangchencui useofradiomicstoimprovediagnosticperformanceofpiradsv21inprostatecancer AT songbin useofradiomicstoimprovediagnosticperformanceofpiradsv21inprostatecancer |